Submitted by endpointsnews6292 in health
Pfizer’s mRNA flu vaccine met both primary endpoints in the 18- to 64-year-old population in an ongoing Phase III trial, the company announced on Tuesday morning. However, executives are no longer shooting for a 2024 launch. While Pfizer initially pegged a po…